CHC™
Soft Tissue Repair
ResearchPlatform Expansion
Key Facts
About Corline Biomedical
Corline Biomedical, founded in 2005 and based in Uppsala, Sweden, has developed the Corline Heparin Conjugate (CHC™), a unique macromolecular technology that mimics the natural blood-compatible lining of blood vessels. The company operates a dual business model, generating revenue by supplying its CHS™ coating to medical device partners while advancing its proprietary pipeline, Renaparin® and Cytoparin™, in high-value regenerative medicine fields like kidney transplantation and cell therapy. Listed on Nasdaq First North (CORLINE), Corline leverages a strong scientific foundation of over 100 publications to drive innovation and partnerships in areas of significant unmet clinical need.
View full company profileTherapeutic Areas
Other Soft Tissue Repair Drugs
| Drug | Company | Phase |
|---|---|---|
| Renaparin® | Corline Biomedical | Preclinical |
| Rotium Bioresorbable Wick | Nanofiber Solutions | Commercial |
| FORTIFY TRG® Tissue Repair Graft | Sanara MedTech | Approved/Commercial |
| FORTIFY FLOWABLE® Extracellular Matrix | Sanara MedTech | Approved/Commercial |